Gen-1 Molecule A — Main Track
L0 — Joint IP Pool (Root Certificate)
JOINT IP POOL — Co-owned Asset
BioAlpha Inc.
55% upstream share
→
Molecule A
Primary root — L0
←
ImmuneLab GmbH
45% upstream share
Both co-owners recoup R&D advances before any downstream split activates
↓
RECOUP GATE
Cost Recovery Gate
Gross revenue minus advances → residual unlocks downstream
↓
L1 — Technology & Process Inputs (CMC Layer)
CHO Cell Line
CellCo BV — 1.2% COGS
Platform B
MNC nanoparticle delivery — L1
Aux. Patent Pool
3rd-party — ~0.5% net
ANTI-STACKING CAP
3rd-party process fees (1.2% + 0.5%) deducted from global royalty pool — MNC floor: Global cap — min 3% net sales
Revenue Tier Trigger
>$500M: 8% → 11% escalation
↓
L2 — Clinical Indication Nodes
Oncology Program
Lung / Gastric / CRC — L2
Immunology Program
RA / IBD / Rare auto — L2
ACCRUAL MODE
Accrual Mode
Real-time Net Sales split
↓
L3 — Regional Commercialization Licensees (Sales rights only — MNC retains global manufacturing)
US Licensee
NorthAm Pharma
APAC Licensee
PanAsian Bio
RoW Licensee
GlobalGen Ltd.
ADJ. STREAM
Adjustment Stream
Retro correction — PBM lag
↓
L4 — Geo-regulatory & Legal Switch Matrix
US / EU — ASYMMETRIC PATENT TERM MATRIX
Lung oncology
Core patent expired
↓
Generic competition
Red ocean market
↓
Royalty rate: ZERO
Gastric oncology
Indication patent + PTE active
↓
Exclusivity extended
Protected market
↓
Tiered royalty: 8-11%
APAC / CN — COMPULSORY LICENSE TRIGGER
Normal state
Commercial terms apply
↓
Public health crisis
TRIPS Art.31 triggered
↓
Revenue Tier
8-11% Royalty
or
Compulsory License
Govt. Compensation
Molecule A2
Parallel Track
Branched from L0
SAR data license fee
20% royalty to L0
Molecule A2
2nd-gen — t1/2 22h — L5
↓
Isolated from Gen-1 risks:
— Independent PTE clock
— No compulsory license risk
— Patent cliff shielded
— Own clinical pipeline
↓
Own Recoup Gate
Separate A2 cost recovery before A2 royalty split
↓
Independent Clinical Programs
New indications
Once-weekly dosing
↓
Global Commercialization
Independent regional licensees
Isolated from Gen-1 terms